Skip to content

Chemed CHE Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Intrinsic Value

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Intrinsic Value at other companies

Belden logo
BeldenBDC
$1.13M-20.8%
The J.M. Smucker Company logo
The J.M. Smucker CompanySJM
$34.3M+23.8%
Repligen logo
RepligenRGEN
116.8K
McCormick & Company, Incorporated logo
McCormick & Company, IncorporatedMKC
$4.6M+39.4%
MSCI logo
MSCIMSCI
$2.32M
Ametek logo
AmetekAME
$154.9M+32.2%

Other financials

Income statement

See full
Revenue$657.5M+1.6%
Gross profit$215.8M-0.3%
Operating income$84.6M-10.7%
Net income$66.3M-7.6%
EPS (diluted)$4.84-0.4%

Balance sheet

See full
Cash & equivalents$16.9M-90.3%
Total debt$236.9M+63.3%
Total equity$848.0M-28.2%
Total assets$1.5B-11.0%

Cash flow

See full
Operating cash flow$88.2M+169%
CapEx$17.1M+28.9%
Free cash flow$71.1M+265%

Valuation

See full
Market cap$5.79B-42.3%
Enterprise value$6.01B-39.6%
P/E22.3×-10.2×
P/S2.3×-1.8×

Profitability

See full
Gross margin32.4%-2.4pp
Operating margin12.9%-2.7pp
Net margin10.2%-2.2pp
FCF margin14.8%+2.2pp

Returns & leverage

See full
Return on equity25.6%-0.5pp
Debt / equity0.3×+0.2×
Current ratio0.9×-0.9×

Where this comes from

Reported directly by Chemed in its filing.

Tagged under the XBRL concept che:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalIntrinsicValue.

The official record: Chemed’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Chemed's share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Chemed's share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value?
Chemed (CHE) reported share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value of $468.25K in Q4 2025.
How has Chemed's share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value changed year-over-year?
Chemed's share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value increased by 46.1% year-over-year, from $320.5K to $468.25K.
What is the long-term trend for Chemed's share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value?
Over 4 years (2021 to 2025), Chemed's share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value has grown at a 12.4% compound annual growth rate (CAGR), from $1.17M to $1.87M.
What does share based compensation arrangement by share based payment award equity instruments other than options vested in period total intrinsic value mean?
The total intrinsic value of non-option equity instruments, such as restricted stock units or performance shares, that vested during the period. This metric highlights the value transferred to employees as their equity awards become non-forfeitable.